AbbVie shares have risen over 53% in 2024 driven by strong sales of immunology drugs Skyrizi and Rinvoq, which are offsetting Humira's decline faster than expected. However, the company faces challenges with a negative shareholders’ equity of -$6.6 billion and high debt of $72.86 billion, raising concerns about leverage and future patent cliffs. Analysts are divided, with a consensus price target suggesting 13% upside, but some models indicate significant downside. Investors are advised to watch upcoming earnings and pipeline developments before making major moves, as the stock balances strong growth potential against financial risks.
SkinMedica, part of Allergan Aesthetics under AbbVie, has launched a Regenerative Science Advisory Board composed of leading skin health experts to guide future innovation. The company also expanded its R&D facility in Irvine, California, integrating...
Big pharmaceutical companies are confronting a $300 billion loss in drug patents by 2030, prompting a surge in acquisitions of mid-size biotech firms with promising drug pipelines. In 2026, biopharma deal values are expected to exceed $250 billion, t...
